DVAX - NASDAQ
Dynavax Technologies Corporation
$15.50
+0.0000%Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
At a Glance
Live SnapshotDynavax Technologies Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Dynavax Technologies Corporation Income Statement
DVAX • NASDAQ
| Dynavax Technologies Corporation Income Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 | Dec 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
277.2M | 232.3M | 722.7M | 439.4M | 46.6M | 35.2M | 8.2M | 327K | 11M | 4.1M | 11M | 11.3M | 9.7M | 21.6M | 24M | 40.3M | 37.1M | 14.1M | 4.8M | 14.7M | |
GROSS PROFIT | ||||||||||||||||||||
(49.4M) | (50.2M) | (262.2M) | (173.6M) | (13.9M) | (19.4M) | (21.8M) | (1.2M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (299K) | (980K) | (980K) | (980K) | (1M) | (698K) | (0.0) | |
227.8M | 182.1M | 460.5M | 265.9M | 32.6M | 15.8M | -13.6M | -867K | 11M | 4.1M | 11M | 11.3M | 9.7M | 21.3M | 23M | 39.3M | 36.1M | 13.1M | 4.1M | 14.7M | |
OPERATING INCOME | ||||||||||||||||||||
(231.9M) | (219.1M) | (177M) | (131.4M) | (107.9M) | (150.7M) | (139.7M) | (93.5M) | (121.8M) | (109.1M) | (102.3M) | (77.7M) | (77.3M) | (69.2M) | (71.5M) | (55.4M) | (61.2M) | (85.2M) | (65.7M) | (37.1M) | |
(170.4M) | (152.9M) | (131.4M) | (100.2M) | (79.3M) | (75M) | (64.8M) | (27.4M) | (37.3M) | (22.2M) | (17.8M) | (26.9M) | (28.2M) | (17.6M) | (16.9M) | (15.7M) | (15.5M) | (18.3M) | (14.8M) | (9.3M) | |
(61.6M) | (54.9M) | (46.6M) | (32.2M) | (28.6M) | (62.3M) | (75M) | (65M) | (84.5M) | (86.9M) | (84.6M) | (50.9M) | (49.1M) | (51.3M) | (53.7M) | (38.7M) | (44.8M) | (65.9M) | (50.1M) | (27.9M) | |
-4.1M | -37M | 283.5M | 134.5M | -75.2M | -134.8M | -153.3M | -96M | -110.7M | -105.1M | -91.3M | -66.5M | -67.6M | -47.6M | -47.6M | -15.1M | -24.1M | -71.1M | -65M | -22.5M | |
PRE-TAX INCOME | ||||||||||||||||||||
(6.8M) | (6.8M) | (6.7M) | (11.2M) | (19.1M) | (17M) | (9.3M) | (0.0) | (0.0) | (572K) | (35K) | (0.0) | (2.4M) | (2M) | (1.7M) | (124K) | (9.2M) | (1.7M) | (0.0) | (0.0) | |
29.7M | 25.2M | 1.2M | -11M | -17.8M | -13.6M | -5.5M | 1.3M | 755K | -367K | 156K | 116K | -2.1M | -1.9M | -1.6M | 54K | -7.4M | 2.4M | 0.0 | 0.0 | |
(0.0) | (11.3M) | -1M | -1M | (0.0) | (13.4M) | -70K | -486K | (0.0) | (317K) | (433K) | -348K | -293K | (299K) | (980K) | (980K) | (980K) | (1M) | (698K) | (0.0) | |
35M | 32.7M | 10.8M | -57M | -18K | -17.8M | -5.6M | 851K | -1.7M | -1.7M | 589K | -232K | -2.4M | -1M | -9.7M | -12K | -2.4M | 2.4M | 3.2M | 1.9M | |
30.9M | -4.4M | 294.3M | 77.5M | -75.2M | -152.6M | -158.9M | -95.2M | -112.4M | -106.8M | -90.7M | -66.7M | -69.9M | -48.6M | -57.3M | -30.6M | -20.8M | -60M | -52.1M | -20.6M | |
NET INCOME | ||||||||||||||||||||
(3.5M) | (2M) | (1.1M) | (808K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -476K | (0.0) | -116K | (0.0) | (0.0) | (0.0) | (0.0) | -3.3M | (372K) | -8.8M | (0.0) | |
27.3M | -6.4M | 293.2M | 76.7M | -75.2M | -152.6M | -158.9M | -95.2M | -112.4M | -106.8M | -90.7M | -66.7M | -69.9M | -48.6M | -57.3M | -30.6M | -20.8M | -60M | -52.1M | -20.6M |
SEC Filings
DVAX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 29, 2025 | December 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 16, 2025 | October 15, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 21, 2025 | August 21, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | June 17, 2025 | June 11, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 13, 2025 | May 08, 2025 | 2025 |
Related Guides
Continue your DVAX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.